LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Charles River Laboratories, Captain T Cell Enter Manufacturing Deal MT
Charles River Laboratories International, Inc and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy CI
Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 MT
The job report just threw a spanner in the works Our Logo
Mizuho Initiates Charles River Laboratories International With Neutral Rating, $235 Price Target MT
ANALYST RECOMMENDATIONS : Lyft, Amazon, Fedex, Xpo, Unilever... Our Logo
Charles River Laboratories Opens New Contract Vivarium Space in Massachusetts MT
The first rate cut Our Logo
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville CI
ANALYST RECOMMENDATIONS : American Airlines, Salesforce, Five Below, Tesla, Okta... Our Logo
Transcript : Charles River Laboratories International, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:00 AM
Transcript : Charles River Laboratories International, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 10:00 AM
Charles River Laboratories, Sanofi Collaborating to Develop Non-Animal Virtual Control Groups for Preclinical Trials MT
Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development CI
Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 MT
Declaration of Voting Results of Charles River Laboratories International Inc CI
JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280 MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235 MT
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 MT
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 MT
Transcript : Charles River Laboratories International, Inc., Q1 2024 Earnings Call, May 09, 2024
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance MT
Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024 CI
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024 CI
Chart Charles River Laboratories International, Inc.
More charts
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
211.6 USD
Average target price
263.1 USD
Spread / Average Target
+24.35%
Consensus
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies